Go to projects

Health

COMPASS

Health
  • Project dates

    2026-2031

  • Website

    compass-care.eu

  • Role of Zabala

    Partner

  • Project led by

    King’s College London & GE Healthcare

62

Partners

25

Countries

€50. 4 M

Total budget

60

Months

Challenge

Cardiotoxicity is a growing and often under-detected consequence of modern cancer therapies, with significant implications for patient survival, quality of life and healthcare systems. Current tools have limited predictive value and there is a lack of reliable biomarkers, meaning cardiovascular complications are often detected too late. At the same time, fragmentation between oncology and cardiology, together with challenges in data integration, hinders timely diagnosis, coordinated care and effective long-term patient monitoring.

Solution

COMPASS addresses these challenges by developing a comprehensive, patient-centred clinical pathway to improve the cardiovascular health of cancer patients and survivors. By integrating advanced diagnostics, novel biomarkers, real-world data and AI-driven analytics, the project enables earlier detection of cardiotoxicity, supports personalised treatment decisions, and facilitates continuous patient monitoring.

Impact

COMPASS will deliver significant scientific, economic and societal impact by developing novel biomarkers, large-scale datasets and validated artificial intelligence models to advance research in cardio-oncology. The project will contribute to improving healthcare system efficiency by supporting the development of cost-effective, evidence-based care pathways that are integrated and harmonised across Europe. In addition, it will enhance the quality of life of cancer patients and survivors through earlier detection, more personalised care and improved long-term cardiovascular outcomes.

Consortium

COMPASS is an ambitious project supported by the Innovative Health Initiative (IHI JU), bringing together 62 international partners from 25 countries. Its aim is to improve cardiovascular health among cancer patients and survivors by developing a patient-centred cardio-oncology care pathway supported by novel biomarkers, clinical data and artificial intelligence. Full list of consortium partners.

This project is supported by the Innovative Health Initiative Joint Undertaking (IHI JU) under grant agreement 101253264. The JU receives support from the European Union’s Horizon Europe research and innovation programme and COCIR, EFPIA, Europa Bío, MedTech Europe, Vaccines Europe, and ECG Médica S.L. (Ascires).

Laura Sesma

“COMPASS brings together cutting-edge science, digital innovation and multidisciplinary collaboration to transform the way cardiovascular risks are managed in cancer care, enabling more proactive, personalised and equitable healthcare for patients across Europe.”

Laura Sesma

Team leader expert in European Programmes in the Health Area

Team involved

  • Laura Sesma

    Laura Sesma

    Pamplona Office

    Team leader expert in European Programmes in the Health Area

  • Arantxa Iborra

    Brussels Office

    Consultant in Dissemination of European Projects

No es el sector, es el proyecto

Lo importante no es seguir avanzando, sino saber hacia dónde ir. Y nuestra tasa de éxito del 37% demuestra que en Zabala sabemos guiar a nuestros clientes.

Áreas de especialización

¿Quieres saber qué podemos ofrecerte?

Nuestra brújula es el cliente; nuestra misión es resolver sus problemas, guiándole para que la innovación se convierta en su clave de competitividad.

Conoce nuestros servicios